Top Markets
Coin of the day
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
株式のランク #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
株価
$0.00042815
最終同期: 2024-02-27
時価総額
$13.55K
変化(1日)
0.03%
変化(1年)
0.00%
GB
取引 ReNeuron Group plc (RENE)

カテゴリー

ReNeuron Group plc(RENE)の配当利回りの履歴
ReNeuron Group plc(銘柄コード: RENE)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
ReNeuron Group plc(RENE)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)